PTC\SB(08x (08-03)
Approved for use through 07/31/2006 OMB 085-1-2031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it contains a valid OMB control number.

	Application Number			
NEODIATION DIOCI COURT	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Russ		ssell Keene	
(Not for submission under 37 CFR 1.99)	Art Unit		TBD	
,	Examiner Name	TBD		
	Attorney Docket Numb	er	W-358-02	

				U.S.	PATENTS	Remove		
Examiner Initial*	Cite No Patent Number		Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	2437139		1948-03-02	W. R. Tucker			
	2	2846121		1958-08-05	H. r. Ronnebeck			
	3	2972888		1961-02-28	J. C. Lamkin			
	4	3098506		1963-07-23	G. F. Spragens			
	5	3119251		1964-01-28	M. A. Bowers			
	6	3201922		1965-08-24	R. Villalobos			
	7	3530721		1970-09-29	J. Hrdina			
	8	3630371		1971-12-28	Jiri Hrdina			

| Application Number | Fing Date | Fing Da

	9	3683701		1972-08-15	Gunther, et al			
	10	3698428		1972-10-17	Darrell L. Gastin			
	11	3744512		1973-07-10	Roger O. Billman			
	12	4394263		1983-07-19	Werner Dosch			
	13	4454749		1984-06-19	Guillemin, et al			
	14	4602657		1986-07-29	Anderson, William L.			
	15	4655095		1987-04-07	Manuel A. Russo			
If you wis	h to a	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.		Add	
U.S.PATENT APPLICATION PUBLICATIONS Remove								
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee of Applicant Releval		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1							-
If you wish to add additional U.S. Published Application citation information please click the Add button. Add								
FOREIGN PATENT DOCUMENTS Remove								

Application Number | Fing Date | Fing Date | Finst Named Inventor | Russell Keene | Art telt | TED | Examiner Name | TED | Attorney | Attorney | TED | ATTORNEY

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴		Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							
If you wish	h to a	dd additional Foreign	Patent Docume	nt citation	information p	please click the Add butto	n Add	_
			NON-PAT	ENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, ctyl andor country where published.					Τs		
	1							
If you wis	h to a	dd additional non-pai	ent literature do	cument cit	tation informa	tion please click the Add	button Add	
				EXAMINE	R SIGNATUI	RE		
Examiner	Signa	ture				Date Considered		
						formance with MPEP 609 with next communication		

See Knd. Octobe of USPTO Platein Documents at year, <u>USPTO, OCT</u> or MPEP 901.04. * Enter office in all issued the document, by the two-letter code (WIPO Standard STA). * Enter planese patient connectine, the analysis of the payer of the region of the Engener purpose control the patient document. * (*And of document by the appropriate symbol as andicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if the patient document is a characteristic and the standard st

| Application Number | Fing Date | Find Da

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):	
---	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jamie H. Rose/	Date (YYYY-MM-DD)	2006-08-17
Name/Print	Jamie H. Rose	Registration Number	45.054

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$3 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.